Vetter ML, Wadden TA, Teff KL, Khan ZF, Carvajal R, Ritter S, et al
It says anyone with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome should avoid GLP-1 agonists entirely, and recommends a comprehensive thyroid evaluation first
Blue Cross Blue Shield of Massachusetts (BCBSMA) will stop covering every GLP-1 written for obesity on January 1, 2026, unless an employer pays extra for a rider
kidney disease
Renue NAD+ Renue Renue 8 53 15 Renue 2.5 Renue Chris B
Am J Phys Heart Circ Phys 298:H2174H2191 Wieczor R, Gadomska G, Ruszkowska-Ciastek B, Stankowska K, Budzynski J, Fabisiak J, Suppan K, Pulkowski G, Rosc D (2015) Impact of type 2 diabetes on the plasma levels of vascular endothelial growth factor and its soluble receptors type 1 and type 2 in patients with peripheral arterial disease